We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The need for new asthma treatments
- Poor asthma control in the real world
- Asthma deaths and therapy (UK)
- Managing mild asthma: SYGMA 1
- Managing mild asthma: SYGMA 2
- NOVEL-START study
- GINA
- Severe asthma
- Severe asthma: inflammatory phenotypes
- Unmet needs in asthma therapy
- Targeting T2 (eosinophilic) inflammation
- Interleukin-5 in asthma
- Anti-IL-5 and asthma exacerbations
- Benralizumab in severe asthma
- Interleukin-4/13 in asthma
- Dupilumab: severe asthma
- Dupilumab in asthma
- GATA-3 inhibition
- TSLP and asthma
- Anti-TSLP: severe asthma
- IL-33 and asthma
- DP2 antagonists in asthma
- Fevipiprant in severe asthma
- Targeting neutrophil inflammation
- Anti-TNF in severe asthma
- CXCR2 antagonist in severe asthma
- IL-17 expression in asthma
- Anti-IL-17R in asthma
- Macrolide in severe asthma
- New anti-inflammatory treatments
- PDE4 inhibitors
- Roflumilast in asthma
- Tiotropium in poorly controlled asthma
- Mast cell inhibitors
- Masitinib in severe asthma
- A cure for asthma?
- Conclusions: new asthma treatments
Topics Covered
- Need for new asthma treatments
- Poor control of asthma in the real world
- Anti-inflammatory relievers
- Difficult and severe asthma
- Targeting T2 asthma
- Anti-IL-5 antibodies
- IL-4Rα antibody -Anti-alarmins
- Non-T2 asthma
- Targeting neutrophilic asthma
- Phosphodiesterase-4 inhibitors
- Long-acting muscarinic antagonists
- Mast cell inhibitors
- Cures for asthma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Barnes, P. (2021, September 29). New drugs for asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2024, from https://doi.org/10.69645/TBFI8779.Export Citation (RIS)
Publication History
Financial Disclosures
- Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Peter Barnes from Imperial College London.
I'm going to talk about some of the new drugs and treatment approaches for asthma.
0:10
We currently have very effective asthma treatments,
but they could be improved in several ways in the future.
Existing drugs do have side effects because they're not specific for asthma.
There is a need for most specific asthma targeted therapies.
Patients prefer tablets to inhalers because they're easier
to use and it certainly easier to develop these treatments.
There's evidence that there's improved compliance with oral versus inhaled medications.
We still have a problem in managing severe asthma which by
definition is not very responsive to current therapies.
This reflects a relative steroids resistance in these patients.
We don't have any drugs at the moment that are truly "disease
modifying" which continue to control the disease when their stocked.
In particular, we don't have a cure for asthma which is
a once given treatment that switches off the disease completely.
1:15
Despite the fact that we have very effective treatments for asthma in the real world.
This is a study looking at asthma control using questionnaires.
What you can see is that around half of the patients are poorly controlled.
In fact, only 28 percent in this survey were well controlled.
Despite the fact that all of these patients had been prescribed inhaled steroids and most
of these given inhaled steroid in combination with a long acting beach or agonists.
This problem is seen throughout the world and still persist.
Here is an even larger study of 8,000 asthmatics.
Again, almost half are uncontrolled.
Many patients are having to have courses of oral steroids and visit
the emergency department and around 12 percent of patients are hospitalized.
Now the reason for poor control of asthma despite
prescription of effective treatments is that there
is a low adherence particularly to
inhaled steroid therapies which in the real world is less than 20 percent.
But also there's a problem of poor inhaler technique.
These two factors account for most of the poor asthma control in the real world.